Терапевтический архив (Oct 2022)

Mechanical circulatory support in refractory cardiogenic shock: retrospective register study

  • Polina P. Savvinova,
  • Vladimir N. Manchurov,
  • Boris L. Haes,
  • Dmitry V. Skrypnik,
  • Elena J. Vasilieva,
  • Alexander V. Shpektor

DOI
https://doi.org/10.26442/00403660.2022.09.201886
Journal volume & issue
Vol. 94, no. 9
pp. 1094 – 1098

Abstract

Read online

Cardiogenic shock (CS) is one of the main causes of death in patients with acute myocardial infarction (AMI). Mortality from CS remains high, despite the introduction of myocardial revascularization and the use of modern medication. The use of mechanical circulatory support (MCS) is promising, it could reduce mortality in patients with AMI and CS. Aim. To define effectiveness and safety of MCS in patients with AMI and CS. Materials and methods. Our study includes 47 patients with AMI and refractory CS, who were treated at the University Clinic of Cardiology of the Yevdokimov Moscow State University of Medicine and Dentistry from 2019 to 2022. Mortality and various complications were analyzed in patients with refractory CS, patients who received and did not receive mechanical circulatory support (intra-aortic balloon pump IABP, extracorporeal membrane oxygenation ECMO). Results. Mortality among patients with refractory CS was significantly lower in the subgroup of patients who received mechanical circulatory support devices (59% vs 93%; p=0.02). Moreover, reliability is achieved mainly due to patients in whom were VA-ECMO implanted (p=0.02), not IABP (p=0.16). Conclusion. VA-ECMO associated with reduced mortality and should be considered in patients with AMI and refractory CS. Further research is needed to select the optimal method of mechanical circulatory support in patients with CS.

Keywords